OCTANOIC ACID

Molecular Excipient

Mwt. LogP HBD HBA PSA RB CSP3
143.0 1.1 0 2 40.0 6 0.88
CAS
124072
UNII
OBL58JN025
SYNONYMS
ZINC ID(s)
Availability
Present in 81 ZINC catalogs

Known Active Genes

This compound has been observed to have activity at 10μM or less against the following gene(s).
Name Description Classification
SLC22A8 Solute carrier family 22 member 8 Transporter / Electrochemical-Transporter
SLC22A6 Solute carrier family 22 member 6 Unclassified / Unclassified

Clinical Trials

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
Code Date Title Phase Status
NCT01211782 AC-1204 Long-term Efficacy Response Trial (ALERT Protocol) Phase 2/Phase 3 Withdrawn
NCT02232152 2014-12-01 CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery Phase 1 Recruiting
NCT02168907 2014-12-01 CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Phase 1 Recruiting
NCT02168140 2014-09-01 CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma Phase 1 Recruiting
NCT01864525 2013-07-01 Effects of Octanoic Acid for Treatment of Essential Voice Tremor Phase 1/Phase 2 Recruiting
NCT01839981 2013-07-01 CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 1 Recruiting
NCT01835041 2013-04-01 CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer Phase 1 Recruiting
NCT01848327 2013-02-01 Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis Phase 2 Recruiting
NCT01468948 2011-10-01 Octanoic Acid for Essential Tremor Phase 1 Completed
NCT01110772 2009-05-01 Comparison of Iodine + Isopropyl Alcohol Versus Iodine + Antimicrobial Sealant for Skin Preparation Phase 4 Recruiting
NCT00848172 2009-02-01 Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor Phase 1/Phase 2 Completed

(Browse) Purchasable Analogs in ZINC

Dosages

Route Formulation Per Unit Dose
Intravenous Injection 0.01%

More Information

Usage Over Time

Comments